epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.
EPI-214, Phase III. Recruiting
Heart failure with reduced ejection fraction
CTS-209 added to standard care in heart failure with reduced ejection fraction. Sponsor: Contoso Pharmaceuticals (fictional), Cardiovascular.
QTLs at a glance
Data to September 30th 2026. Each measure links to its chart below.
Quality tolerance limits (acceptable ranges, in ICH E6(R3)), most important first. Priority is how likely this study's design makes a breach, times how strongly the evidence links the measure to a reliable result. Each has an early-warning line, a limit and a critical line where the study's power would fall to the escalation level.
Rank
QTL
Likelihood
Impact
Why it is likely here
Watched at sites by
Warning
Limit
Critical
1
Stopped study treatment earlyEvidence grade B
3
2
Placebo or no-added-treatment control arm (PD-05)From the design: What does the control arm receive? Placebo or no added treatment
Study drug at the siteTighter KRI threshold at sites in Turkey, for currency crisis with a fixed pharmaceutical exchange rate (Turkey 2018–2026). The QTL itself stays study-wide.
12.5%
15%
22%
2
Ineligible patients randomisedEvidence grade B
2
2
Restrictive eligibility criteria and protocol complexity (EB-04)From the design: How many non-essential exclusions does the protocol carry? One or two
Eligibility criteria exclude patients (comorbidity, age, performance status, language) (PB-02)From the design: How many non-essential exclusions does the protocol carry? One or two
Restrictive eligibility criteria (organ function, brain metastases, prior or concurrent malignancy, HIV, laboratory thresholds, performance status) (PD-01)From the design: How many non-essential exclusions does the protocol carry? One or two
Number of eligibility criteria and complexity growth (PD-02)From the design: How many non-essential exclusions does the protocol carry? One or two
Missing primary endpoint data: running rate by month
Month
Patients
Rate
Sep 2024
5
0%
Dec 2024
20
0%
Mar 2025
42
0%
Jun 2025
89
3.4%
Sep 2025
146
4.1%
Dec 2025
193
4.1%
Mar 2026
241
3.3%
Jun 2026
291
3.4%
Sep 2026
350
3.4%
Oct 2026
361
3.3%
The acceptable range is the drop-out the study's power calculation allowed for (planner parameters, D24); the early-warning line sits at two-thirds of it
Lost to follow-up or withdrew consent
Within range% of patients; benchmark median 3.7%
Show data
Lost to follow-up or withdrew consent: running rate by month
Month
Patients
Rate
Mar 2024
5
0%
Jun 2024
20
0%
Sep 2024
42
0%
Dec 2024
89
0%
Mar 2025
147
0%
Jun 2025
194
0%
Sep 2025
242
0.4%
Dec 2025
292
0.7%
Mar 2026
352
0.6%
Jun 2026
400
1%
Sep 2026
456
1.1%
Oct 2026
472
1.1%
epiClinical assumption: above the combined benchmark median of 3.7% and in line with published case studies that set limits around 4% for unknown survival status
Patients needed before a QTL is judged: 50. epiClinical assumption: QTL rates are unstable with few patients, and many early breaches in vendor data were noise (review note 01).
Breaches and decisions
Breach
Stopped study treatment early
Early warning November 2025; left the range February 2026
Status
Evaluated; actions proposed
What the evaluation found
Most patients who stopped did so after the dose step-up at week 12, reporting dizziness or low blood pressure; older patients were affected most. Sites that adjusted the dose as the protocol's guidance describes saw about half the stopping rate of those that did not.
Why it matters
Stopping treatment dilutes the measured treatment effect. The sample size allowed for 15% of patients stopping, so if the trend continues the study may lose the power to show a difference.
Proposed CAPAs
Keep following every patient who stops treatment, so their outcome data are still collected.
Protects the missing-data QTLs: outcomes collected after stopping treatment keep the result reliable (review note 01).
Reissue the dose-adjustment guidance and run a short refresher with each site's investigator and study nurse.
Evidence grade D. No quantitative evidence that site re-training changes outcomes; included because the finding points to how sites apply the guidance.
Have the medical monitor review each stop with the investigator within a week, to see whether it could have been managed with a dose adjustment.
A process step with no outcome evidence; it makes each decision visible and recorded.
A fictional scenario written to show how a breach is evaluated. No real patients or studies are described.
Critical lines assume each study was designed for 80% power at a two-sided 5% level, and mark where power would fall to 70%. Missing outcome data can bias a result well before it costs power, so its limit, not its critical line, is the one to act on.